Zum Hauptinhalt springen
Amtlicher EU-KennzeichnungsnameGlossareintrag 28752

THIOCTIC ACID

Dieser Eintrag bestätigt einen amtlichen gebräuchlichen Inhaltsstoffnamen für die EU-Kennzeichnung kosmetischer Mittel. Er bestätigt für sich genommen nicht, dass der Stoff zulässig, unbeschränkt oder sicher ist.

Globale Belegübersicht

Die ermittelte Identität hat übereinstimmende regulatorische Belege in 1 von 13 indizierten Marktdatensätzen: 1 Ländereinträge und 0 EU-Anhangseinträge. Jedes Ergebnis und jede Belegslücke ist unten aufgeführt.

1 Märkte mit Belegen
Geprüfte Märkte
13
Märkte mit Belegen
1
Belegslücken
12
Ermittelte Kennungen
2

Ermittelte Stoffidentität

CAS:1077-28-7
EC:214-071-2
Einträge im Inhaltsstoffindex:
THIOCTIC ACID
Kosmetische Funktionen: ANTIOXIDANT

1,2-Dithiolane-3-pentanoic acid, (+/-)-

3 übereinstimmende oder gemeldete Namen
THIOCTIC ACIDThioctic acid [JAN]Thioctic acid

Regulatorische Belege in allen 13 Märkten

Öffnen Sie jeden übereinstimmenden Eintrag, um Geltungsbereich, Konzentration, Bedingungen, Warnhinweise und die Version der amtlichen Quelle zu sehen.

Wischen oder scrollen Sie horizontal, um Datenabdeckung und nächste Schritte zu sehen.

MarktErgebnisEinträgeDatensatzBedeutung / nächster Schritt
European Union
EU
Kein Treffer gefunden0
Complete annex dataset
Regulation (EC) 1223/2009 consolidated to 1 May 2026
No annex match only means that these five annexes did not return a match; CosIng identity data and other EU obligations still need review.
Great Britain
GB
Kein Treffer gefunden0
Complete consolidated annex dataset
GB retained Regulation 1223/2009 schedules, effective 15 August 2026
No annex match is not approval and does not cover Northern Ireland, which follows the applicable EU framework.
Canada
CA
Kein Treffer gefunden0
Complete Hotlist snapshot
Health Canada Cosmetic Ingredient Hotlist, 13 August 2025
The Hotlist is an administrative compliance tool, not an exhaustive safety approval list.
New Zealand
NZ
Kein Treffer gefunden0
Complete schedules dataset
Cosmetic Products Group Standard schedules effective 1 January 2026
The searchable spreadsheet is an aid; the legal Group Standard and incorporated notices remain authoritative.
ASEAN
ASEAN
Kein Treffer gefunden0
Complete regional annex dataset
ASEAN Cosmetic Directive annexes 2026-1, 22 June 2026
Regional annex coverage does not replace member-state implementation dates, notifications or national deviations.
China
CN
Kein Treffer gefunden0
Complete prohibited catalogues plus official-source workflow
NMPA 2021 banned catalogues plus dynamic IECIC List I/List II system current since 2025
IECIC listing is not blanket approval; absence may require the new cosmetic ingredient route, and restrictions are checked separately.
Japan
JP
Restricted1Eintrag öffnen 1
Complete Standards appendices dataset
MHLW Standards for Cosmetics official English source and Japanese amendments checked for the imported snapshot
Prüfen Sie jeden verknüpften Eintrag und die genauen Bedingungen.
South Korea
KR
Kein Treffer gefunden0
Complete current appendix dataset
MFDS Notice 2026-19, effective 18 March 2026
Korean source wording is canonical and other positive lists/notices may still apply to the formulation.
United States
US
Kein Treffer gefunden0
Complete enumerated federal ingredient rules
eCFR Title 21 issue date 27 August 2026
FDA has no general approved-cosmetic-ingredient catalogue; absence from these sections is not approval or proof of safety.
Australia
AU
Kein Treffer gefunden0
Complete cosmetic-relevant Poisons Standard subset plus official workflow
Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026
An AICIS Inventory match is not cosmetic approval; no Inventory match can indicate a new, exempted, reported or confidential introduction.
Brazil
BR
Kein Treffer gefunden0
Complete prohibited dataset plus current restricted-list workflow
ANVISA RDC 1.029/2026 and RDC 1.030/2026, published 15 June 2026
RDC 1.030/2026 amends rather than replaces the prohibited baseline, and the second restricted-list revision was still under consultation in July 2026.
India
IN
Kein Treffer gefunden0
Complete current Part 2 dataset plus official workflow for Parts 1, 3 and 4
Cosmetics Rules 2020 plus current BIS IS 4707 parts (1:2020, 2:2025, 3:2025, 4:2022)
The standards are separate controlled publications; absence from a locally indexed excerpt is not permission.
Saudi Arabia
SA
Kein Treffer gefunden0
Complete official list index
SFDA live prohibited/restricted lists, snapshot 30 August 2026
No list match is not permission; Gulf/SFDA product, claim, notification and technical requirements still apply.
Keine Marktzeilen entsprechen diesem Filter.

Übereinstimmende Markteinträge und Bedingungen

Chemische Identität und Eigenschaften

Chemische 2D-Struktur aus PubChem für CAS 1077-28-7
CAS 1077-28-7PubChem CID 864

alpha Lipoic acid

Lipoic acid is a heterocyclic thia fatty acid comprising pentanoic acid with a 1,2-dithiolan-3-yl group at the 5-position. It has a role as a geroprotector and a fundamental metabolite. It is a member of dithiolanes, a heterocyclic fatty acid and a thia fatty acid. It is functionally related to an octanoic acid. It is a conjugate acid of a lipoate. — ChEBI

IUPAC-Name
5-(dithiolan-3-yl)pentanoic acid
Summenformel
C8H14O2S2
Molekulargewicht
206.3 g/mol
Exakte Masse
206.04352203 Da
XLogP3
1,7
Topologische polare Oberfläche
87,9 Ų
Wasserstoffbrücken-Donoren
1
Wasserstoffbrücken-Akzeptoren
4
Kovalente Einheiten
1
Definierte Stereozentren
0

Auch bekannt als

thioctic acidalpha-Lipoic acid6,8-Thioctic acidBiletanDL-6,8-Thioctic acidThioctsanthioctateThiocacid
16 weitere gemeldete Namen
ThioctanTioctic AcidAcidum thiocticumA-lipoicum acidumLipoic acid, dl-Lipoic acid, alphabiomoliponAlphaLipogammabiomo liponespa liponAlpha LipogammaPleomix AlphaVerla LiponAlphaLipon StadaAlpha Lippon ALAlpha Lipon Stada
Kennungen in externen Datenbanken

Belege aus weiteren wissenschaftlichen Datenbanken

NIH PubChem PUG-View
Exakter Kennungstreffer864

Attributed physical-property, hazard, environmental and use annotations.

  • Note: This chemical does not meet GHS hazard criteria for 6.5% (28 of 430) of reports. Quelle: European Chemicals Agency (ECHA)
  • Signal: Warning Quelle: European Chemicals Agency (ECHA)
  • GHS Hazard Statements: H302 (93.5%): Harmful if swallowed [Warning Acute toxicity, oral]; H315 (48.6%): Causes skin irritation [Warning Skin corrosion/irritation]; H317 (46.5%): May cause an allergic skin reaction [Warning Sensitization, Skin]; H319 (47%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]; H411 (46.5%): Toxic to aquatic life with long lasting effects [Hazardous to the aquatic environment, long-term hazard] Quelle: European Chemicals Agency (ECHA)
  • Precautionary Statement Codes: P261, P264, P264+P265, P270, P272, P273, P280, P301+P317, P302+P352, P305+P351+P338, P321, P330, P332+P317, P333+P317, P337+P317, P362+P364, P391, and P501 (click each P-code to see the statement) Quelle: European Chemicals Agency (ECHA)
  • ECHA C&L Notifications Summary: Aggregated GHS information provided per 430 reports by companies from 16 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.; Reported as not meeting GHS hazard criteria per 28 of 430 reports by companies.; There are 14 notifications provided by 402 of 430 reports by companies with hazard statement code(s).; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. Quelle: European Chemicals Agency (ECHA)
  • Note: This chemical does not meet GHS hazard criteria for 42.3% (52 of 123) of reports. Quelle: European Chemicals Agency (ECHA)
  • GHS Hazard Statements: H302 (57.7%): Harmful if swallowed [Warning Acute toxicity, oral]; H315 (31.7%): Causes skin irritation [Warning Skin corrosion/irritation]; H319 (31.7%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]; H335 (31.7%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation]; H412 (19.5%): Harmful to aquatic life with long lasting effects [Hazardous to the aquatic environment, long-term hazard] Quelle: European Chemicals Agency (ECHA)
  • Precautionary Statement Codes: P261, P264, P264+P265, P270, P271, P273, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement) Quelle: European Chemicals Agency (ECHA)
  • ECHA C&L Notifications Summary: Aggregated GHS information provided per 123 reports by companies from 8 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.; Reported as not meeting GHS hazard criteria per 52 of 123 reports by companies.; There are 7 notifications provided by 71 of 123 reports by companies with hazard statement code(s).; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. Quelle: European Chemicals Agency (ECHA)
  • Health Effects: Acute exposure to cholinesterase inhibitors can cause a cholinergic crisis characterized by severe nausea/vomiting, salivation, sweating, bradycardia, hypotension, collapse, and convulsions. Increasing muscle weakness is a possibility and may result in death if respiratory muscles are involved. Accumulation of ACh at motor nerves causes overstimulation of nicotinic expression at the neuromuscular junction. When this occurs symptoms such as muscle weakness, fatigue, muscle cramps, fasciculation, and paralysis can be seen. When there is an accumulation of ACh at autonomic ganglia this causes overstimulation of nicotinic expression in the sympathetic system. Symptoms associated with this are hypertension, and hypoglycemia. Overstimulation of nicotinic acetylcholine receptors in the central nervous system, due to accumulation of ACh, results in anxiety, headache, convulsions, ataxia, depression of respiration and circulation, tremor, general weakness, and potentially coma. When there is expression of muscarinic overstimulation due to excess acetylcholine at muscarinic acetylcholine receptors symptoms of visual disturbances, tightness in chest, wheezing due to bronchoconstriction, incre Quelle: Toxin and Toxin Target Database (T3DB)
  • Toxicity Summary: ALA is generally considered a safe drug. A daily dose of 200 mg/day to 2400 mg/day of ALA is deemed safe without significant adverse effects. However, there is no reported safe dose in children.; A notable case in literature demonstrated status epilepticus (SE) that subsided within a few days. The seizures were treated per normal standards for SE.; In the last 2 decades, there have been few reported cases of ALA toxicity in humans. Most of these cases occur in children and are treatable. Though there is no established lethal dosage of ALA for humans, studies have shown that a high dose of 121 mg/kg body weight/day was associated with alterations in liver enzymes and liver function. Therefore, there are potentially harmful adverse effects from overdosing on ALA, and more studies are necessary to determine the toxicity. Quelle: StatPearls
  • Toxicity Summary: (R)-lipoic acid is a cholinesterase or acetylcholinesterase (AChE) inhibitor. A cholinesterase inhibitor (or 'anticholinesterase') suppresses the action of acetylcholinesterase. Because of its essential function, chemicals that interfere with the action of acetylcholinesterase are potent neurotoxins, causing excessive salivation and eye-watering in low doses, followed by muscle spasms and ultimately death. Nerve gases and many substances used in insecticides have been shown to act by binding a serine in the active site of acetylcholine esterase, inhibiting the enzyme completely. Acetylcholine esterase breaks down the neurotransmitter acetylcholine, which is released at nerve and muscle junctions, in order to allow the muscle or organ to relax. The result of acetylcholine esterase inhibition is that acetylcholine builds up and continues to act so that any nerve impulses are continually transmitted and muscle contractions do not stop. Among the most common acetylcholinesterase inhibitors are phosphorus-based compounds, which are designed to bind to the active site of the enzyme. The structural requirements are a phosphorus atom bearing two lipophilic groups, a leaving group (such as Quelle: Toxin and Toxin Target Database (T3DB)
  • Uses: Nutrition, biochemical research /Thioctic acid, dl-form/ Quelle: Hazardous Substances Data Bank (HSDB)
  • Uses: THERAPEUTIC CATEGORY: Treatment of liver disease; antidote to poisonous mushrooms (Amanita species). Quelle: Hazardous Substances Data Bank (HSDB)
  • Uses: Use (kg; approx.) in Germany (2009): >7500; Consumption (g per capita; approx.) in Germany (2009): 0.0916; Calculated removal (%): 96.4 Quelle: NORMAN Suspect List Exchange
  • Uses: For nutritional supplementation, also for treating dietary shortage or imbalance. Quelle: Toxin and Toxin Target Database (T3DB)

Zugeordnet durch: Existing checksum-valid CAS to unique PubChem CID match. Abgerufen: 2026-08-31. Quelleneintrag öffnen

Wissenschaftliche Klassifizierungen und Gefahrenannotationen liefern Kontext und ersetzen nicht die oben gezeigte marktspezifische regulatorische Entscheidung.

Weitere Quellenabdeckung und Trefferstatus
QuelleErgebnisGeprüft
NIH PubChem PUG-ViewExakter Treffer2026-08-31

Ein erfasster Nicht-Treffer ist ein nützlicher Beleg dafür, dass die Quelle geprüft wurde; er ist keine Behauptung, dass der Stoff anderswo nicht existiert.

Am 2026-09-02 von NIH PubChem durch prüfsummengültigen CAS-Abgleich abgerufen. Chemische Eigenschaften ersetzen nicht die regulatorische Entscheidung auf dieser Seite.

Weitere maßgebliche Stoffrecherche

Jeder Link durchsucht die jeweilige Quelle nach dieser Identität. Ein Link ist ein Recherchepfad und keine Behauptung, dass die Quelle einen exakten Eintrag enthält. Was jede Quelle ist und welches rechtliche Gewicht sie hat

Diesen Eintrag weiterverwenden

In einer Rezeptur prüfenEigenständigen Vergleich öffnen

Amtliche Quelle und Geltungsbereich

Importiert aus dem Durchführungsbeschluss (EU) 2025/1175 der Kommission (Datensatzversion EU 2025/1175). Das Glossar liefert gebräuchliche Inhaltsstoffnamen für die nach Artikel 19 Absatz 1 Buchstabe g vorgeschriebene Inhaltsstoffliste; es ist keine Zulassungs- oder Sicherheitsliste.

Amtlichen Beschluss öffnen